Bio Insights
Contributor since: 2011
Latest Articles
Why La Jolla Pharma Has Very Favorable Risk/Reward
An Overview Of The Multibillion-Dollar Colorectal Cancer Diagnostics Market
ThermoGenesis Merging With TotiRx - Heating Up Cell Therapy Mergers And Acquisitions
Research Notes On Intercept And NASH: A Liver Disease Investors Should Watch
Baupost Group Acquires Huge Stake In Kindred Biosciences
Vital Stem Cell Data And Development Coming In 2014
Neostem Could Rally On Phase II Results
Kindred Bio: New, Hot Play On Animal Health
NeoStem: Continued Progress And 2014 Catalysts
A Bull/Bear Outline For The Unilife Debate
Opportunities For Sorrento After Acquisition Of ADC Tech
Unilife May Finish The Year With >100% YTD Gains
Ampio: Anticipating Data For Exciting DME Therapy Optina
2 Pharmas That Should Move After 55th ASH Meeting
Ohr Pharma: A Pure 2014 Catalyst Play With Large Potential
Categorizing Biology Investments And 2 Niche Market Stock Picks
Amarin: Our Last Analysis Before ANCHOR Adcom For Vascepa
2 Biotechs Targeting Brain Cancer
Biotech-Focused Baker Bros. Accumulates These 3 Stocks
Phase III Trial Ruins Prosensa's Drisapersen, Sarepta Rallies Strongly
Clovis: After Data, Company Looking For Acquisition
Amyloidosis Heats Up On Biotech M&A
3 Compelling Oncology Biotechs From Rodman & Renshaw 2013
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Inovio And OncoSec Retain Higher Valuations, More Data Anticipated Soon
Cancer Genetics: High-End Diagnostics For Personal Cancer Treatment
Amarin Regains Ahead Of Vital Q4 Catalysts
Targeting An Untapped Female Sexual Dysfunction Drug Market
Biotech: A Scattershot Of Stem Cell Plays Following Yesterday's Bloodbath
Dendreon: Too Little, Too Late?
Ampio Momentum Continues After Positive Initial Phase III Data
Positive Data And Investor Interest Uphold Stemline's Momentum